ETFChannel.com
PTCT Description — PTC Therapeutics Inc

PTC Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. Co. has the following products, Translarna™ (ataluren) and Emflaza® (deflazacort), for the treatment of Duchenne muscular dystrophy, a rare, life threatening disorder. Co.'s gene therapy product candidates for rare monogenic diseases that affect the central nervous system (CNS) include PTC- Aromatic L-Amino Acid Decarboxylase (AADC) for the treatment of AADC deficiency, a rare CNS disorder arising from reductions in the enzyme AADC that results from mutations in the dopa decarboxylase gene.

Company Name: 
PTC Therapeutics Inc
Website: 
www.ptcbio.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding PTCT: 
34
Total Market Value Held by ETFs: 
$437,863,330
Total Market Capitalization: 
$2,857,000,000
% of Market Cap. Held by ETFs: 
15.33%
 ETF   PTCT Weight   PTCT Amount 
 VTI   0.01%   $87,568,917         
 VB   0.06%   $75,327,091         
 IWM   0.12%   $66,504,315         
 XBI   0.87%   $65,874,613         
 VBK   0.16%   $43,653,842         
 VXF   0.05%   $39,483,938         
 IWO   0.18%   $17,236,603         
 VHT   0.04%   $9,071,441         
 IWN   0.06%   $7,309,971         
 VTWO   0.12%   $7,081,218         
List of all 34 ETFs holding PTCT »
Quotes delayed 20 minutes

Email EnvelopeFree PTCT Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Buy (3.09 out of 4)
30th percentile
(ranked lower than approx. 70% of all stocks covered)

Analysts Forecast:
PTCT Price Target

Based on data provided by Zacks Investment Research via Quandl.com

ETFs Holding PTCT | PTC Therapeutics Inc | ETF Channel | www.ETFChannel.com

Copyright © 2010 - 2022, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.